TY - JOUR
T1 - Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab
AU - Korsten, Peter
AU - Sweiss, Nadera J.
AU - Nagorsnik, Ulf
AU - Niewold, Timothy B.
AU - Grne, Hermann Josef
AU - Gross, Oliver
AU - Mller, Gerhard A.
N1 - Funding Information:
Support: Dr Sweiss received funding from the Foundation for Sarcoidosis Research , Abbott , Bristol-Myers Squibb , Genenetech , and Centocor for the study of biologic therapy in sarcoid.
PY - 2010/12
Y1 - 2010/12
N2 - Tumor necrosis factor α (TNF-α) inhibitors are used in the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn disease, ankylosing spondylitis, and juvenile idiopathic arthritis. Use of TNF inhibitors is associated with the induction of autoimmunity (systemic lupus erythematosus, vasculitis, psoriasis, and sarcoidosis/sarcoid-like granulomas). We report a case of interstitial granulomatous nephritis in a patient with ankylosing spondylitis after 18 months of treatment with adalimumab. Previously reported cases of sarcoid-like reactions secondary to the use of TNF-α inhibitors involved the liver, lung, lymph nodes, central nervous system, and skin. Granulomatous nephritis after adalimumab treatment has not been described. Close observation of patients undergoing treatment with TNF inhibitors for evolving signs and symptoms of autoimmunity is required. Organ involvement is unpredictable, which makes correct diagnosis and management extremely challenging.
AB - Tumor necrosis factor α (TNF-α) inhibitors are used in the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn disease, ankylosing spondylitis, and juvenile idiopathic arthritis. Use of TNF inhibitors is associated with the induction of autoimmunity (systemic lupus erythematosus, vasculitis, psoriasis, and sarcoidosis/sarcoid-like granulomas). We report a case of interstitial granulomatous nephritis in a patient with ankylosing spondylitis after 18 months of treatment with adalimumab. Previously reported cases of sarcoid-like reactions secondary to the use of TNF-α inhibitors involved the liver, lung, lymph nodes, central nervous system, and skin. Granulomatous nephritis after adalimumab treatment has not been described. Close observation of patients undergoing treatment with TNF inhibitors for evolving signs and symptoms of autoimmunity is required. Organ involvement is unpredictable, which makes correct diagnosis and management extremely challenging.
KW - Ankylosing spondylitis
KW - Granulomatous interstitial nephritis
KW - Sarcoidosis
KW - Tumor necrosis factor α (TNF-α) inhibitors
UR - http://www.scopus.com/inward/record.url?scp=78649443776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649443776&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2010.08.019
DO - 10.1053/j.ajkd.2010.08.019
M3 - Article
C2 - 20974510
AN - SCOPUS:78649443776
SN - 0272-6386
VL - 56
SP - e17-e21
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -